Adage Capital Partners GP L.L.C. Has $220.77 Million Holdings in Boston Scientific Corporation $BSX

Adage Capital Partners GP L.L.C. decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 20.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,055,365 shares of the medical equipment provider’s stock after selling 536,748 shares during the quarter. Adage Capital Partners GP L.L.C. owned 0.14% of Boston Scientific worth $220,767,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BSX. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the 1st quarter worth approximately $26,000. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter valued at approximately $26,000. Sound Income Strategies LLC lifted its stake in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the last quarter. Kilter Group LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at $30,000. Finally, Princeton Global Asset Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at $32,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. UBS Group boosted their price target on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Canaccord Genuity Group reiterated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research report on Thursday, October 23rd. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. The Goldman Sachs Group restated a “buy” rating and issued a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a report on Friday, November 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $124.43.

Boston Scientific Price Performance

BSX stock opened at $92.58 on Friday. The company has a market capitalization of $137.24 billion, a P/E ratio of 49.51, a PEG ratio of 1.85 and a beta of 0.67. The company has a fifty day moving average price of $98.85 and a 200-day moving average price of $101.64. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 143,095 shares of company stock worth $14,228,950 over the last ninety days. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.